SolmazSahebjamMD

Hematologic Oncology, Neuro-Oncology

Director of Neuro-oncology Program in National Capital Region, Deputy Director of Clinical Research in National Capital Region, Associate Professor (PAR) of Oncology

Join to view full profile

Dr. Sahebjam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sahebjam's full profile

Already have an account?

Office
5255 Loughboro Road Northwest
Washington, DC 20016
Phone+1 202-660-6500

Fax+1 202-660-6501

Education & Training

St Vincent HospitalResidency, Internal Medicine, 2006 - 2008
Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 2005 - 2006
Iran University of Medical SciencesClass of 2000

Certifications & Licensure

DC State Medical License 2022 - 2027
FL State Medical License 2013 - 2025
MD State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Royal College of Physicians and Surgeons of CanadaBoard of Internal Medicine
Royal College of Physicians and Surgeons of CanadaBoard of Medical Oncology

Clinical Trials

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07
Active, not recruiting
Phase 3
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
Terminated
Phase 2
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Start of enrollment: 2014 Mar 10
Active, not recruiting
Phase 1
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas Start of enrollment: 2015 Jul 28
Completed
Phase 1
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Start of enrollment: 2018 Mar 16
Completed
Phase 1
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Start of enrollment: 2019 Feb 13
Completed
Phase 1
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Start of enrollment: 2020 Dec 10
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran
Clinical Cancer Research. 2024-02-01
Towards gender equity in neuro-oncology.
Solmaz Sahebjam, Heather Leeper
Neuro-Oncology Practice. 2024-02-01
6 citations
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.
Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung
NPJ Breast Cancer. 2023-11-17

Journal Articles

Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma
David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology

Authored Content

Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020